CommercialCoverageHigh impact
[Virginia] Updates to Carelon Medical Benefits Management Clinical Appropriateness Guidelines
Anthem BCBS·VA · Oncology, Vascular Surgery, Cardiology +2 more·Provider Bulletin
Effective date
Nov 15, 2026
We identified it
Aug 5, 2026
Summary
Carelon Medical Benefits Management updated clinical appropriateness guidelines effective November 15, 2026, with significant changes to coverage criteria for vascular procedures, genetic testing, and cancer-related molecular testing. Key changes include new indications for drug-eluting beads in liver cancer treatment, expanded genetic testing criteria for multiple cancer types, new allowances for cyanoacrylate ablation in varicose vein treatment, and exclusion of certain procedures (PFO closure in patients >60 years, ctHPV DNA testing in oropharyngeal carcinoma, and immunoembolization therapy). Billing teams must update prior authorization workflows and claims adjudication rules to reflect these additions and deletions.
Action Required
By November 15, 2026: (1) Billing and prior authorization team must update all authorization protocols to reflect new covered indications: inframalleolar angioplasty for critical limb ischemia with tissue loss, cyanoacrylate ablation for perforators, drug-eluting beads (DEB-TACE) for primary/metastatic liver malignancy, pelvic vein embolization for venous-origin chronic pelvic pain affecting ADLs, portal vein embolization for primary liver tumors, varicocele embolization, and collateral embolization in complex congenital heart disease. (2) Update denial protocols to exclude coverage for: flow-limiting dissection as atherectomy indication, PFO closure in patients >60 years, ctHPV DNA testing for oropharyngeal carcinoma, immunoembolization therapy, and isolated labial/lower extremity varicose veins without pelvic symptoms. (3) Update genetic testing authorization rules to reflect expanded criteria for breast cancer (stages IIB-IIIC and inoperable IIB), prostate cancer (niraparib and talazoparib added), colorectal cancer (PIK3CA testing, KRAS p.G12C), pancreatic cancer (removed stage requirements), metastatic prostate cancer (broadened indications, removed mCSPC high-burden requirement), thyroid cancer (removed gene number restriction, added TMB testing), and unknown primary cancers (MSI testing added). (4) Ensure all components of genetic liquid biopsy and somatic tumor tests demonstrate clinical utility per new requirement. (5) Update denial language to specify RNA fusion/expression/whole transcriptome analysis using ctRNA are not medically necessary. (6) Create reflex protocols allowing tissue biopsy after liquid biopsy if actionable variant not detected or result uninformative. (7) Document required testing components for biliary tract cancer comprehensive molecular panels. (8) Update prior auth forms for Duplex ultrasound requirements (>3 months after initial varicose vein treatment). Failure to implement by effective date will result in inappropriate claim denials for newly covered procedures and incorrect approvals for newly excluded services, creating revenue leakage and compliance issues.